The potential to use PspA and other pneumococcal proteins to elicit protection against pneumococcal infection
The potential to use PspA and other pneumococcal proteins to elicit protection against pneumococcal infection
复制标题
DOI：
10.1016/s0264-410x(99)00511-3
复制
发表时间：
2000-02-25
期刊：
影响因子：
5.5
通讯作者：
Swift, A
中科院分区：
文献类型：
--
作者：
Briles, DE;Hollingshead, S;Swift, A
肺炎球菌蛋白单独、相互结合或与荚膜多糖-蛋白偶联物结合可能是有用的肺炎球菌疫苗成分。四种可能用于疫苗的蛋白质是PspA、溶肺素、PsaA和PspC。在小鼠载体模型中，PsaA和PspC是最有效的疫苗蛋白。在这其中，PsaA是最能引起对运输的保护的。然而，PspA和溶血素联合使用可能比单独使用任何一种蛋白更能引起对肺部感染和可能的败血症的免疫。最近，重组家族1 PspA的一期试验已在人体中完成。PspA具有安全性和免疫原性，将免疫血清稀释至1/400后0.1 ml注射可保护小鼠免于肺炎链球菌致死性感染。在这些条件下，免疫前血清不具有保护作用，免疫人血清保护小鼠免受表达PspA主要家族（1和2）的肺炎球菌感染，以及两种被测试的肺炎球菌荚膜类型：3和6。(C) 2000 Elsevier Science Ltd.版权所有。
Pneumococcal proteins, alone, in combination with each other, or in combination with capsular polysaccharide-protein conjugates may be useful pneumococcal vaccine components. Four proteins with a potential for use in vaccines are PspA, pneumolysin, PsaA, and PspC. In a mouse model of carriage, PsaA and PspC were the most efficacious vaccine proteins. Of these, PsaA was the best at eliciting protection against carriage. However, a combination of PspA and pneumolysin may elicit stronger immunity to pulmonary infection and possibly sepsis than either protein alone. Recently, a phase one trial of a recombinant family 1 PspA was completed in man. PspA was observed to be safe and immunogenic, Injection of 0.1 ml of immune serum diluted to 1/400 was able to protect mice from fatal infection with S. pneumoniae. Under these conditions, preimmune serum was not protective, The immune human serum protected mice from infections with pneumococci expressing either of the major PspA families (1 and 2) and both of the pneumococcal capsular types tested: 3 and 6. (C) 2000 Elsevier Science Ltd. All rights reserved.